These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 27096698)
1. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy. Smith L; Mosley J; Yates J; Caswell L J Pharm Pharm Sci; 2016; 19(1):137-46. PubMed ID: 27096698 [TBL] [Abstract][Full Text] [Related]
2. Evolocumab: A Review in Hyperlipidemia. Keating GM Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308 [TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Blom DJ; Dent R; Castro RC; Toth PP Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264 [TBL] [Abstract][Full Text] [Related]
4. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management? Stein EA Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553 [TBL] [Abstract][Full Text] [Related]
5. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia. Sible AM; Nawarskas JJ; Anderson JR Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466 [TBL] [Abstract][Full Text] [Related]
6. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview. Noel ZR; Beavers CJ Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630 [TBL] [Abstract][Full Text] [Related]
8. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
9. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061 [TBL] [Abstract][Full Text] [Related]
10. [Up to date lipid lowering treatment]. Paragh G; Karádi I Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. Okere AN; Serra C Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279 [TBL] [Abstract][Full Text] [Related]
12. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Gupta S Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050 [TBL] [Abstract][Full Text] [Related]
13. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia. Sultan Alvi S; Ansari IA; Khan I; Iqbal J; Khan MS Free Radic Biol Med; 2017 Jul; 108():394-403. PubMed ID: 28412198 [TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis. Strålberg T; Nordenskjöld A; Cao Y; Kublickiene K; Nilsson E Eur J Clin Invest; 2019 Jul; 49(7):e13113. PubMed ID: 30921469 [TBL] [Abstract][Full Text] [Related]
15. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. Whayne TF Am J Cardiovasc Drugs; 2016 Apr; 16(2):83-92. PubMed ID: 26596726 [TBL] [Abstract][Full Text] [Related]
16. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Page MM; Watts GF Expert Opin Drug Metab Toxicol; 2015; 11(9):1505-15. PubMed ID: 26293511 [TBL] [Abstract][Full Text] [Related]
17. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia]. Saußele T Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362 [TBL] [Abstract][Full Text] [Related]
18. Statins and Their Effect on PCSK9-Impact and Clinical Relevance. Taylor BA; Thompson PD Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084 [TBL] [Abstract][Full Text] [Related]
19. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]